Bristol Myers Squibb (CELG-RI) EBT Margin Growth (5y) (2014 - 2026)

Bristol Myers Squibb (CELG-RI) EBT Margin Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Bristol Myers Squibb - - 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 535.00
Dec 31, 2025 10,618.00
Sep 30, 2025 406.00
Jun 30, 2025 -161.00
Mar 31, 2025 2,934.00
Dec 31, 2024 304.00
Sep 30, 2024 -836.00
Jun 30, 2024 -1,777.00
Mar 31, 2024 -13,049.00
Dec 31, 2023 -1,061.00
Sep 30, 2023 -1,859.00
Jun 30, 2023 750.00
Mar 31, 2023 -982.00
Dec 31, 2022 349.00
Sep 30, 2022 -282.00
Jun 30, 2022 -870.00
Mar 31, 2022 -2,518.00
Dec 31, 2021 -521.00
Sep 30, 2021 -1,312.00
Jun 30, 2021 -1,989.00